This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk

  • participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks
  • primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke
  • the CANVAS Program was a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials (1,2)

Results:

The study authors concluded:

  • "...in two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal..."

Key findings:

  • CANVAS Program met its primary objective of demonstrating the cardiovascular safety and efficacy of canagliflozin
  • canagliflozin use was associated with an increased risk of amputation which should be taken into consideration when prescribing this agent
  • data suggest a favorable benefit/risk profile with canagliflozin treatment in many patients with type 2 diabetes and high cardiovascular risk

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.